Tafamidis
Tafamidis is the medicine inside Vyndamax and Vyndaqel. The US label describes it as a selective stabilizer of transthyretin, the protein involved in transthyretin amyloidosis. The label gives its indication as the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalization. The atlas holds no trial results for it.
Also called Vyndamax · Vyndaqel
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 1545063. Two FDA applications: NDA212161 (Vyndamax, tafamidis) and NDA211996 (Vyndaqel, tafamidis meglumine, whose marketing status is discontinued in the Drugs@FDA record although the label record still names the brand). One label record, version 15, covers both brands. The mechanism comes from that label.
Trials at a glance
The figures count the 2 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 2
- Phase 3 or 4
- 2
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | All statuses |
|---|---|---|
| Phase 3 | 2 | 2 |
| All phases | 2 | 2 |
Conditions these trials study
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- A selective stabilizer of transthyretin (US drug label).
Claims and evidence
Context Adults with transthyretin amyloid cardiomyopathy (wild-type or hereditary), as described in the US label of Vyndaqel and Vyndamax
- Recipient
- Adult
- Population
- Adults with cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), as the label states its indication.
- Care setting
- Prescription medicine taken by mouth; the label record states no care setting
- Geography
- United States (labeling approved by the US Food and Drug Administration)
- Life stage
- Adults
- Follow-up
- Not applicable (regulatory and labeling statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (label indication)
- Excluded
- None stated
The openFDA records list two tafamidis applications, both with an original submission approved on 3 May 2019: NDA212161 for Vyndamax (tafamidis; class Type 2 - New Active Ingredient; applicant FOLDRX PHARMS), listed as a prescription product, and NDA211996 for Vyndaqel (tafamidis meglumine; class Type 1 - New Molecular Entity), listed as discontinued. One label record (version 15, effective 12 May 2026) still names both brands and says they are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Applies to Adult Adults with transthyretin amyloid cardiomyopathy (wild-type or hereditary), as described in the US label of Vyndaqel and Vyndamax
- Certainty method
- Not assessed
- Limitations
- An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The discontinued status of Vyndaqel is the marketing status in the openFDA application record, and the label record still lists the brand, so the two sources are given side by side without reconciling them. The two applications are for different forms of the substance (the meglumine salt and tafamidis itself). The label record is a copy and may not show later changes. openFDA says not to rely on its data for decisions about medical care. The atlas gives no dose.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (14)
-
Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)
- Locator
- results[0].application_number
- How it applies
- Application number of Vyndamax.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)
- Locator
- results[0].sponsor_name
- How it applies
- Applicant.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)
- Locator
- results[0].products[0].brand_name
- How it applies
- Brand name.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)
- Locator
- results[0].products[0].active_ingredients[0].name
- How it applies
- Active ingredient.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[1].submission_status_date
- How it applies
- Date of the original approval, written as eight digits.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[1].submission_class_code_description
- How it applies
- Class of the original submission.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA212161 (openFDA Drugs@FDA record)
- Locator
- results[0].products[0].marketing_status
- How it applies
- Marketing status of Vyndamax.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)
- Locator
- results[0].application_number
- How it applies
- Application number of Vyndaqel.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)
- Locator
- results[0].products[0].brand_name
- How it applies
- Brand name.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)
- Locator
- results[0].products[0].active_ingredients[0].name
- How it applies
- Active ingredient.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[0].submission_status_date
- How it applies
- Date of the original approval, written as eight digits.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[0].submission_class_code_description
- How it applies
- Class of the original submission.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA211996 (openFDA Drugs@FDA record)
- Locator
- results[0].products[0].marketing_status
- How it applies
- Marketing status of Vyndaqel.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports Vyndaqel and Vyndamax drug label (openFDA record, set id 1b4121ee-a733-4456-a917-be2603477839)
- Locator
- results[0].indications_and_usage[0]
- How it applies
- Indication in the label record.
- Retrieved
- Source effective date
- 2026-05-12
- Source state
- Current
- Version fingerprint
bedf5f095796dfdac9f9344d3cc362424ca403537b52a20b748c8cda7b0eb226- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/terms/, https://open.fda.gov/license/; licence page fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The label text is the manufacturer's labeling as FDA publishes it; check the openFDA documentation for a not-in-the-public-domain warning before quoting beyond short passages. The raw file is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
VYNDAMAX
No label from the application holder was found in the openFDA label dataset for application NDA212161. This page does not show another labeler's label in its place.
VYNDAQEL
No label from the application holder was found in the openFDA label dataset for application NDA211996. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact US label indication: cardiomyopathy of transthyretin amyloidosis in adults: Cardiac amyloidosis
Applies to Adult Adults with transthyretin amyloid cardiomyopathy (wild-type or hereditary), as described in the US label of Vyndaqel and Vyndamax
The openFDA records list two tafamidis applications, both with an original submission approved on 3 May 2019: NDA212161 for Vyndamax (tafamidis; class Type 2 - New Active Ingredient; applicant FOLDRX PHARMS), listed as a prescription product, and NDA211996 for Vyndaqel (tafamidis meglumine; class Type 1 - New Molecular Entity), listed as discontinued. One label record (version 15, effective 12 May 2026) still names both brands and says they are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalization.Limitations. An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The discontinued status of Vyndaqel is the marketing status in the openFDA application record, and the label record still lists the brand, so the two sources are given side by side without reconciling them. The two applications are for different forms of the substance (the meglumine salt and tafamidis itself). The label record is a copy and may not show later changes. openFDA says not to rely on its data for decisions about medical care. The atlas gives no dose.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 2
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Record details
- Record id
cardio:tafamidis- Content hash
41621e727b1a3a4da5ae713b99fa1cba48d0bbc23344dd54f70ba372f7483478